CHICAGO, Ill. – By Shim Hyun-tai / Korea Biomedical Journal Correspondent – VUNO Inc., a medical AI software company, highlights its four main product lines under the concept of “past, present and future of the application of artificial intelligence (AI) in clinical practice” a senior executive said on Wednesday.
“Most of the companies in the AI medical imaging industry had gone in the same direction to achieve great results in everything before the Covid-19 outbreak,” said VUNO radiologist Hong Eun-kyoung. “Looking back over the past two years, however, it is no longer meaningful to just do well because everyone is doing well.”
VUNO wanted to highlight how the currently applied AI solutions are used in real life, Hong said.
“At the company level, I have reflected on the role of our clinical practice, and as a radiologist, I have reflected on how effectively we can use the artificial in the workflow of the radiology department. , especially with regard to the ongoing pandemic, ”Hong said in an interview with Korea. Biomedical review on the fringes of the Radiological Society of North America (RSNA) 2021 in progress in Chicago, Illinois, USA
Hong added that the company had considered and planned the direction of the necessary solutions in terms of development, and not just “cool” solutions.
Founded in 2014, VUNO now has more than 200 medical AI experts with six physicians leading clinical departments, and around 40% of the workforce is concentrated in research and development, according to Hong.
“As we emphasized at the AI Showcase throughout this convention, we are focused on making upgrades, advancements, new features and developing successive versions in each of our solutions. “Hong said.
She noted that the company’s new VUNO Med-Chest X-ray Pro could report 11 chest abnormalities, compared to just five available in the existing model. The advanced VUNO Med-LungCA can also automatically detect lung nodules in CT scans and predict malignancy.
In addition, VUNO Med-DeepBrain AD can contribute to the early diagnosis of Alzheimer’s disease by analyzing the volumetric information of the brain, beyond helping diagnose neurodegenerative diseases in the previous version, she said. .
In addition, VUNO Med-BoneAge 2.0 provides accurate assessment of bone age independent of adolescence by adding new functionality for analyzing X-ray images of the elbow to the existing solution.
“For me, defining a problem seems to be the most important factor in creating a good AI algorithm, as a clear statement of the purpose of the AI solution would allow it to collect quality data and train it well. “Hong said. “I still wonder if the AI solution is worth paying for from a business perspective.”
VUNO has 10 AI solutions, and six of them have received the Conformite Européenne (CE) mark, some of which are under review by the United States Food and Drug Administration (FDA).
Hong said visitors and overseas attendees here asked him if the solutions would work well in their hospitals because VUNO is a Korean company.
“We used the available data as much as possible in the learning process for AI solutions, and the solutions were validated in other countries through various tasks,” said Hong. “In addition, we are working with foreign hospitals for research purposes and we are preparing to enter the global market when the time is right.”
Hong pointed out that VUNO is working on improving its range of AI solutions and increasing accuracy.
“As a VUNO radiologist, my mission is also to see if and how we can further validate our existing products clinically,” Hong said.